TABLE 2.
Demographics.
| Demographic | Training set (N = 45), median (IQR) or number (%) | Validation set (n = 266), median (IQR) or number (%) | p Value | Total (n = 311) |
|---|---|---|---|---|
| Age | 65 (61–70) | 65 (61–68) | 0.65 | 65 (61–68) |
| Race/ethnicity | 0.09 | |||
| Black | 11 (24.4%) | 34 (12.8%) | 45 (14.5%) | |
| Hispanic | 18 (40%) | 100 (37.6%) | 118 (37.9%) | |
| White | 16 (35%) | 132 (49.6%) | 148 (47.6%) | |
| Prostate-specific antigen | 6.88 (5.05–10.03) | 5.22 (4.30–6.63) | 0.001 | 5.4 (4.4–6.8) |
| Family history of prostate cancer | 11 (24.4%) | 47 (18%) | 0.22 | 58 (18.6%) |
| PCA3 score | 31.1 (13.8–60.3) | |||
| T2:ERG score | 4.78 (0.09–32.12) | |||
| Bacterial toxin genes | 6 (13.3%) | 18 (6.8%) | 0.16 | 24 (7.7%) |
| pks (clbN or clbB) | 3 (6.7%) | 15 (5.6%) | 0.78 | 18 (4.4%) |
| cdt | 0 (0%) | 7 (2.6%) | 0.27 | 7 (1.7%) |
| cnf-1 | 4 (8.9%) | 6 (2.3%) | 0.02 | 10 (2.4%) |
| Prostate cancer | 21 (46.7%) | 131 (49.2%) | 0.87 | 152 (48.9%) |
| Grade group 1 | 10 (22.2%) | 62 (23.3%) | 72 (23.2%) | |
| Grade group 2 | 2 (4.4%) | 32 (12%) | 34 (10.9%) | |
| Grade group 3 | 6 (13.3%) | 20 (7.5%) | 26 (8.4%) | |
| Grade group 4 | 2 (4.4%) | 16 (6%) | 18 (5.8%) | |
| Grade group 5 | 1 (2.2%) | 1 (0.4%) | 2 (0.6%) |
Abbreviation: IQR, interquartile range.